Stock Analysis
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis
Rigel Pharmaceuticals, Inc. (RIGL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Rigel Pharmaceuticals, Inc. (RIGL) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 99/100. Sentiment is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RIGL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $47.24 |
| AIQ Score | 74/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $878.85M |
| P/E Ratio | 2.69 |
| Forward P/E | — |
| EPS | $0.93 |
| Revenue TTM | $78.7M |
| Dividend Yield | 0.00% |
| Beta | 1.17 |
| Volume | 187.17K |
| 52-week range | $24.95-$52.24 |
| RSI 14 | 59.92 |
| 50-Day SMA | $42.54 |
| 200-Day SMA | $36.44 |
| Analyst Price Target | $67.00 |
| Next Earnings | Nov 3, 2026 |
RIGL
OverviewRIGL Stock Analysis Summary
Rigel Pharmaceuticals, Inc. (RIGL) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 99/100. Sentiment is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, RIGL has AIQ Score of 74/100 with Quality base of 99/100 and fading Sentiment at 50/100. Wait for component alignment before adding exposure.
Quality (99/100) leads while Sentiment (50/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.08% stock move · RIGL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RIGL Bullish or Bearish Right Now?
RIGL currently has a bullish overall setup. Quality is the strongest factor at 99/100, while Sentiment is weakest at 50/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 99/100.
- - Momentum is constructive at 67/100.
- - Price is +11.52% above its 50-day SMA.
- - Analyst target implies +41.83% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (32 vs 6).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
RIGL's Technical Analysis Consensus is currently Strong Buy, with 32 buy, 7 neutral, and 6 sell votes. RIGL's 14-day RSI is 59.92, which places the stock in a constructive momentum range. RIGL's beta is 1.17, indicating market sensitivity broadly in line with the market.
What Changed in RIGL?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the RIGL Outlook?
The current bullish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RIGL Decision Framework
Public evidence layers, setup checks, and risk context for Rigel Pharmaceuticals, Inc..
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis
Rigel Pharmaceuticals, Inc. has an AIQ Score of 74/100 in a Bullish regime. Quality is strongest at 99/100. Beta is 1.17, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RIGL is in a Bullish AIQ regime with score 74/100. |
| Signal Conflict | The primary conflict is that quality leads at 99/100 while sentiment lags at 50/100. |
| Factor Evidence | Momentum 67/100 · Value 63/100 · Quality 99/100 · Risk 59/100 · Sentiment 50/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 99/100.
Momentum is 67/100 and RSI (14) is 57.0.
RIGL is in a Bullish regime at 74/100.
Risk factor is 59/100 with beta 1.17 and annual volatility 64.58%.
Current conflict: quality leads at 99/100 while sentiment lags at 50/100.
RIGL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RIGL Fundamentals
RIGL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RIGL Technical Analysis
RIGL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RIGL Stock Catalysts
Track RIGL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RIGL Dividend Analysis
RIGL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RIGL Financial Data
RIGL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RIGL Risk Analysis
RIGL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RIGL Stock News
RIGL stock news, market tone, recent headlines, and catalyst context.
RIGL vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: RIGL · ROIV · RXRX · SRPT · VERA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RIGL Current stock | 74/100 | 63/100 | 67/100 | 59/100 | 0.65 | 64.58% | Current |
| ROIV Roivant Sciences | 57/100 | 34/100 | 78/100 | 61/100 | 2.48 | 46.57% | RIGL vs ROIV |
| RXRX Recursion Pharmaceuticals | 36/100 | 34/100 | 34/100 | 58/100 | -0.19 | 71.78% | RIGL vs RXRX |
| SRPT Sarepta Therapeutics | 55/100 | 64/100 | 67/100 | 38/100 | 0.58 | 81.30% | RIGL vs SRPT |
| VERA Vera Therapeutics | 42/100 | — | 50/100 | 57/100 | 0.72 | 59.35% | RIGL vs VERA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RIGL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RIGL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RIGL Stock FAQ
What is RIGL stock price today?
Rigel Pharmaceuticals, Inc.'s current stock price is $47.24. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RIGL bullish or bearish right now?
RIGL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RIGL's market cap?
RIGL's market cap is $878.85M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RIGL's current P/E ratio?
RIGL's current P/E ratio is 2.69 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RIGL's RSI?
RIGL's 14-day RSI is 59.92 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RIGL above its 50-day and 200-day moving averages?
RIGL is 11.52% from its 50-day SMA and 29.65% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RIGL's next earnings date?
RIGL's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RIGL pay a dividend?
RIGL's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.